Vitti Labs Announces FDA Approval of Phase II IND Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Pulmonary Fibrosis Secondary to Novel Corona Virus Infection (COVID-19)

Vitti Labs announced that the FDA approved their Investigational New Drug Application to move forward with Phase II Outpatient Clinical Trial using a combination of umbilical cord MSCs and MSC Exosomes for the treatment of pulmonary fibrosis secondary to COVID-19.